Cytiva and Veeda Lifesciences drive biopharma innovation with new host cell protein services center

 

• Collaboration to facilitate advanced biologics testing by providing HCP coverage, characterization and quantification assays, and related services to customers globally
• New center will help improve safety, efficacy, and quality in biopharma development
• Combination of Cytiva's analytical technologies with Veeda's extensive service delivery capabilities and regulatory expertise

 

 

November 28, 2025: Cytiva, a Danaher company and a leader in the life sciences industry, is collaborating with Veeda Lifesciences (Veeda Clinical Research Limited), a global contract research organization, to establish a dedicated Host Cell Protein (HCP) Services Center in Bengaluru, India. Focused on impurity analysis and HCP testing, this new center will help biopharmaceutical companies reduce development risks and meet regulatory standards for novel biologics and biosimilars.

 

Dr. Mahesh Bhalgat, Group CEO and Managing Director, Veeda Lifesciences (Veeda Clinical Research Limited), says: “We are delighted to partner with Cytiva to bring deeper scientific insights to biologics manufacturers and enable more robust characterization of biopharmaceutical products. Analytical data is central to product approvals, and our collaboration strengthens the foundation of regulatory approvals of biosimilars.”

 

Supported by Cytiva’s technology and located within Veeda’s facility, the center will serve as a comprehensive analytical hub for manufacturers, researchers, and academic institutions. Using multiple attribute DIGE (differential gel electrophoresis) techniques, it will streamline workflows and enhance speed and accuracy of analysis. The center will generate regulatory-ready data for impurity analysis across recombinant proteins, therapeutic monoclonal antibodies, vaccines, and related modalities. Key services include HCP coverage, characterization and quantification assays, essential for detecting impurities that could compromise product quality and patient safety.

 

This commitment to quality reinforces insights from Cytiva's 2025 Biopharma Index, which highlights growing demand for analytical and digital tools that improve assurance, regulatory review, and process control, helping companies scale production, reduce batch failures, and deliver critical medicines faster.

 

Manoj Kumar R Panicker, General Manager of South Asia, Cytiva, says: "This new center is a bold step toward accelerating innovation and advancing therapeutics. It represents what's possible when science, industry, and purpose unite to shape the future of biopharma excellence."

 

Host cell proteins are process-related impurities from the cells used to manufacture biologics. Even at trace levels, HCP residues can cause toxicity, immune reactions, and affect drug stability. Through this collaboration, the center will use advanced analytical methods combining ELISA and mass spectrometry to help companies assess process effectiveness and ensure quality.

 

As India’s bioeconomy moves toward the USD 300 billion mark by 2030, initiatives such as these reinforce the country’s position as a trusted hub for biologics research, manufacturing, and innovation.

 

 

Cytiva and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. 

 

About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With

15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at Cytiva.com

 

About Veeda Lifesciences

Veeda Lifesciences (Veeda Clinical Research Limited) is a platform providing full service as well as functional service for all the stages of drug development to support biotech and pharmaceutical companies with capabilities ranging from Pre-Clinical to Clinical Pharmacology and Clinical Trials across different modalities. We support multiple therapeutic domains and accelerate pipelines through advanced real-world data capabilities on an AI platform. Committed to quality with sound scientific capabilities, we continuously invest in people and technology to help clients in developing innovative therapies and generic drugs for patients worldwide. Visit: https://veedalifesciences.com/